Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $41

Benzinga · 11/09 11:38
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from $39 to $41.